These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37552495)

  • 1. Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers.
    Pereira SAP; Romano-deGea J; Barbosa AI; Costa Lima SA; Dyson PJ; Saraiva MLMFS
    Dalton Trans; 2023 Aug; 52(33):11679-11690. PubMed ID: 37552495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
    Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
    Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
    Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
    Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.
    Egger AE; Hartinger CG; Renfrew AK; Dyson PJ
    J Biol Inorg Chem; 2010 Aug; 15(6):919-27. PubMed ID: 20364440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
    Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
    Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.
    Biancalana L; Pampaloni G; Marchetti F
    Chimia (Aarau); 2017 Sep; 71(9):573-579. PubMed ID: 30188287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring pta Alternatives in the Development of Ruthenium-Arene Anticancer Compounds.
    Kljun J; Rebernik M; Balsa LM; Kladnik J; Rapuš U; Trobec T; Sepčić K; Frangež R; León IE; Turel I
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
    Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
    Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
    Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
    Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates.
    Renfrew AK; Karges J; Scopelliti R; Bobbink FD; Nowak-Sliwinska P; Gasser G; Dyson PJ
    Chembiochem; 2019 Nov; 20(22):2876-2882. PubMed ID: 31102568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C.
    Ratanaphan A; Temboot P; Dyson PJ
    Chem Biodivers; 2010 May; 7(5):1290-302. PubMed ID: 20491084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
    Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
    Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
    Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
    Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
    Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
    J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
    Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
    J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity of Ru(II) piano-stool complexes with chloroquine and chelating ligands against breast and lung tumor cells: Interactions with DNA and BSA.
    Colina-Vegas L; Villarreal W; Navarro M; de Oliveira CR; Graminha AE; Maia PIDS; Deflon VM; Ferreira AG; Cominetti MR; Batista AA
    J Inorg Biochem; 2015 Dec; 153():150-161. PubMed ID: 26277415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
    Nowak-Sliwinska P; van Beijnum JR; Casini A; Nazarov AA; Wagnieres G; van den Bergh H; Dyson PJ; Griffioen AW
    J Med Chem; 2011 Jun; 54(11):3895-902. PubMed ID: 21534534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
    Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
    Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.